Systemic Therapy in Patients With Metastatic Castration …
May 2, 2025 · What are the treatment options for patients previously treated with ADT alone in castration-sensitive or nonmetastatic castration-resistant prostate cancer (CRPC) setting and …
FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer
1 day ago · FDA approved niraparib, abiraterone acetate, and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer, showing significant rPFS improvement in the …
Metastatic Castration-Resistant Prostate Cancer Facts
Apr 18, 2025 · Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options and prognosis.
The Management of Metastatic Castrate-Sensitive Prostate Cancer…
This commentary highlights 2 international studies on real-world treatment trends and patterns among patients with metastatic castration-sensitive and resistant prostate cancer and how …
FDA approves niraparib plus abiraterone acetate with prednisone …
2 days ago · The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial …
Prostate Cancer, Version 4.2023, NCCN Clinical Practice …
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of …
U.S. FDA approves AKEEGA® as the first precision therapy for …
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of …
How We Treat Metastatic Castration-Sensitive Prostate Cancer
Aug 16, 2024 · Risk Stratifying Metastatic Castration-Sensitive Prostate Cancer Among the numerous available strategies, the best choice of first-line therapy for mCSPC is a contentious …
First-line Systemic Treatment Options for Metastatic Castration ...
Mar 2, 2023 · Key Points Question How can the most effective systemic treatment for heterogeneous metastatic castration-sensitive prostate cancer (mCSPC) be chosen? Findings …
Overview of systemic treatment for recurrent or metastatic castration ...
Jun 19, 2025 · Overview of systemic treatment options for recurrent or metastatic castration-sensitive prostate cancer, including therapeutic approaches and considerations for patient …